Important Safety Information Prescribing Information This website is intended for US residents only.
Sancuso Logo

SANCUSO® (granisetron transdermal system) efficacy

Consistent coverage

The SANCUSO patch delivers consistent, predictable coverage maintained throughout 5 days3

Bioavailability of SANCUSO patch vs daily oral granisetron 2 mg dosing1

Graph showing bioavailability of Sancuso patch
Study design: Phase 1 pharmacokinetic study of 12 healthy white male subjects who were randomly assigned to a sequence of treatments, either oral granisetron (2 mg) for 5 days or the 52 cm2 transdermal patch (34.3 mg granisetron) for 5 days.1,2
  • SANCUSO avoids the peak-trough fluctuations in blood levels seen with daily oral granisetron1
  • Smoother daily pharmacokinetic levels vs daily variability with oral granisetron1
  • Maintains steady control, even through hours 25 to 1201
  • The most common adverse event in patients receiving SANCUSO is constipation (5.4%)3

Stay ahead of CINV

The SANCUSO patch is placed 24 to 48 hours prior to the start of chemotherapy to prevent CINV before it begins1

Control of CINV within the first 24 hours of chemotherapy is pivotal4

Bar graph showing control of CINV within first 24 hours of chemotherapy
  • If antiemetic failure occurs during the first 24 hours following chemotherapy, a patient is more likely to experience delayed emesis in the same cycle4
  • The SANCUSO patch should be applied a minimum of 24 hours before chemotherapy3
  • SANCUSO is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration3

SANCUSO is recommended in the National Comprehensive Cancer Network (NCCN) antiemetic treatment guidelines for the prevention of CINV5

The use of SANCUSO complies with the NCCN recommendation that choice of antiemetic is based on the emetogenicity of the chemotherapy regimen and individual patient factors (eg, partial or complete bowel obstruction, concomitant drug treatments, including opiates)5

Sustained control

SANCUSO provided sustained 5-day controla of CINV6

Patients achieving complete CINV controla with SANCUSO over 5 days of chemotherapy6

Bar graph comparing CINV control with Sancuso over 5 days of chemotherapy
aComplete control is defined as no vomiting/retching, no more than mild nausea, and no rescue medication needed from first dose to 24 hours after last dose of chemotherapy.7

Study design: Phase 3 trial of 637 adult patients with cancer randomized to either SANCUSO patch applied 2 to 4 days prior to multiday moderately emetogenic or highly emetogenic chemotherapy and placebo oral capsule (capsule each day of moderately emetogenic/highly emetogenic administration) or placebo patch and granisetron oral capsule (capsule each day of the moderately emetogenic/highly emetogenic administration).7
  • SANCUSO provided complete control of CINV in 83.9% of patients at day 5 in a pivotal clinical trial7
    • Complete control was defined as no vomiting/retching, no more than mild nausea, and no rescue medication from the first dose to 24 hours after the last dose of chemotherapy7
  • Consistent control achieved in patients with cancer with difficult-to-treat chemotherapy regimens6
  • Patients received moderately emetogenic chemotherapy and highly emetogenic chemotherapy multiday (3-5) regimens7
    • 71% of patients received platinum-based regimens (cisplatin)7
    • 72% of patients received chemotherapy for the first time7

Request a sample

You may have patients with chemotherapy-induced nausea and vomiting (CINV) who are appropriate for SANCUSO. Request a sample at no cost to see if SANCUSO is the right option for your patients.

Request Sample

Connect to stay informed

You may have patients with CINV who are ready for SANCUSO. Now you can receive updates about SANCUSO and learn about new resources as they become available.

Stay Informed
Indication and Important Safety Information

Indication

SANCUSO® (granisetron transdermal system) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.

Important Safety Information

Contraindications

SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.

Warnings and Precautions

Adverse Reactions

The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).

To report suspected adverse reactions, contact Kyowa Kirin, Inc. at 1-800-SANCUSO or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See full Prescribing Information for SANCUSO.

References:
  1. Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Manag Res. 2013;5:179-185. doi:10.2147/​CMAR.S34352.
  2. Howell J, Mason JW, Guillory G, Donachie P. Cardiac safety of a granisetron transdermal system in the treatment of chemotherapy-induced nausea and vomiting. Poster presented at: the 8th Annual Conference of the Hematology/Oncology Pharmacy Association; March 21-24, 2012; Orlando, FL.
  3. SANCUSO [package insert]. Bridgewater, NJ: Kyowa Kirin, Inc.; 2013.
  4. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. Oncologist. 2003;8(2):187-198.
  5. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Antiemesis. National Comprehensive Cancer Network. https://​www.nccn.org/​professionals/​physician_gls/​pdf/​antiemesis.pdf. Updated July 20, 2011. Accessed December 18, 2019.
  6. Data on file, Kyowa Kirin, Inc.
  7. Boccia RV, Gordan LN, Clark G, Howell JD, Grunberg SM; on behalf of the SANCUSO Study Group. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer. 2011;19(10):1609-1617. doi:10.1007/​s00520-010-0990-y.